Implantable cytokine factories designed to deliver immunotherapy directly at the site of disease have taken an important step toward clinical reality. Researchers at Rice University, in collaboration with The University of Texas MD Anderson Cancer Center and clinical partners, have reported results from a first-in-human trial evaluating a novel cell-based platform for localized delivery of interleukin-2 (IL-2) in patients with advanced ovarian cancer.

AI summaries can be wrong sometimes—always verify important details using the source link below.